Claims
- 1. A compound selected from the group consisting of a compound of the formula in whichG is —(CR1R2)n—A—(CR1R2)m—(CR1R3)l—(CR1R2)q—R4 A is selected from the group consisting of a direct bond, —C(O)NR5—, —NR5—C(O)—, —C(O)—, —NR5—, —O—, —S—, —S(O)—, —S(O)2—, (C2-C4)-alkynediyl, (C2-C4)-alkenediyl and (C5-C14)-arylene wherein the arylene residue one, two, three, four or five ring carbon atoms can be replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, or a divalent residue of a 3-membered to 7-membered saturated or unsaturated ring which can contain one or two ring heteroatoms selected from the group consisting of nitrogen, sulfur and oxygen and which can be monosubstituted or disubstituted by a member selected from the group consisting of ═O, ═S and R3, B are individually selected from the group consisting of (C1-C18)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl, (C5-C14)-(C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C8)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C1-C6)-alkoxy, (C1-C6)-alkoxy-(C1-C6)-alkyl-, (C1-C6)-alkoxycarbonyl-, (C1-C6)-alkylcarbonyl-, C5-C14)-arylcarbonyl-, C1-C6)-alkylamino-carbonyl-, (C1-C6)-alkoxy-(C1-C6)-alkoxy-, (C5-C14)-aryl-(C1-C8)-alkylcarbonyl-, (C1-C6)-alkanoylamino-, (C1-C6)-alkylsulfonyolamino-, (C5-C14)-arylsulfonylamino-, (C1-C6)-alkylamino-, di-((C1-C6)-alkyl)amino-, (C1-C6)-alkylsulfonyl-, aminosulfonyl-, (C5-C14)-arylsulfonyl-, (C5-C14)-aryl-(C1-C8)-alkylsulfonyl-, (C5-C14)-aryl and (C5-C14)-heteroaryl; X is selected from the group consisting of hydrogen, NR6R6+, fluorine, chlorine, bromine, —OR6, —SR6, hydroxy-(C1-C6)-alkyl-NH—, (hydroxy-(C1-C6)-alkyl)2N—, amino-(C1-C6)-alkyl-NH—, (amino-(C1-C6)-alkyl)2N—, hydroxy-(C1-C6)-alkyl-O—, hydroxy-(C1-C6)-alkyl-S— and —NH—C(O)—R6); Y is selected from the group consisting of R6, fluorine, chlorine, bromine, cyano, —NR6R6+—, —OR6, —SR6 and hydroxy-(C1-C6)-alkyl-NH; R1 and R2 are individually selected from the group consisting of hydrogen, fluorine, chlorine, cyano, nitro, (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C8)-alkyl-, R6—O—R7, R6—S(O)p—R7, R6S(O)2NHR7, R6OC(O)NHR7 and R6R6′N—R7; R3 is selected from the group consisting of hydrogen, fluorine, chlorine, cyano, nitro, (C1-C18)-alkyl, (C2-C18)-alkenyl, (C2-C18)-alkynyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C8)-alkyl-, R6—O—R7, R6R6+R7, R6C(O)—O—R7, R6C(O)R7, R6OC(O)R7), (R6N(R6)C(O)OR7, R6S(O)pN(R5)R7, R6OC(O)N(R5)R7, R6C(O)N(R5)R7, R6N(R6+)C(O)N(R5)R7, R6N(R6+)S(O)pN(R5)R7, R6S(O)pR7, R6SC(O)N(R5)R7, R6N(R6+)C(O)R7 and R6N(R6+)S(O)pR7, where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by a member selected from the group consisting of R6, fluorine, chlorine, bromine, cyano, trifluoromethyl, R6R6+NR7, nitro, R6OC(O)R7, R6C(O)R7, R6N(R6+)C(O)R7, R6N(R6+)S(O)pR7 and R6—O—R7, and where the R3S are independent of one another and can be identical or different; R4 is selected from the group consisting of —C(O)R8, —C(S)R8, —S(O)pR8, —S(O)pR8, —P(O)R8R8+ and a 4-membered to 8-membered saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; R5 is selected from the group consisting of hydrogen, (C1-C10)-alkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C5-C14)-aryl and (C5-C14)-aryl-(C1-C8)-alkyl; R6 and R6+ are individually selected from the group consisting of hydrogen, (C1-C18)-alkyl, (C3-C18)-alkyl, (C3-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl-, C5-C14)-heteroaryl and (C5-C14)-heteroaryl-(C1-C8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by individual substituents selected from the group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkoxy-(C1-C6)-alkyl-, (C1-C6)-alkoxycarbonyl-, (C1-C6)-alkylcarbonyl-, (C1-C6)-alkylaminocarbonyl-, (C1-C6)-alkoxy-(C1-C6)-alkoxy-, (C5-C14)-arylcarbonyl-, (C5-C14)-aryl-(C1-C8)-alkylcarbonyl-, (C1-C6)-alkanoylamino-, (C5-C14)-arylsulfonylamino-, (C1-C6)-alkylsulfonylamino-, (C1-C6)-alkylamino-, di((C1-C6)-alkyl)amino-, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylaminosulfonyl-, (C5-C14)-arylaminosulfonyl-, (C5-C14)-aryl-(C1-C8)-alkylaminosulfonyl, (C5-C14)-arylsulfonyl-, (C5-C14)-aryl-(C1-C8)-alkylsulfonyl, (C5-C14)-aryl and (C5-C14)-heteroaryl; R7 is (C1-C4)-alkanediyl or a direct bond, where all R7 are independent of one another and can be identical or different; R8 and R8+ are individually selected from the group consisting of hydroxy, (C1-C8)-alkoxy, (C5-C14)-aryl-(C1-C4)-alkoxy-, (C5-C14)-aryloxy, (C1-C8)-alkylcarbonyloxy-(C1-C4)-alkoxy-, (C5-C14)-aryl-(C1-C8)-alkylcarbonyloxy-(C1-C8)-alkoxy-, NR6R6, (di-((C1-C8)-alkyl)amino)carbonylmethyloxy-, (di((C5-C14)-aryl-(C1-C8)-alkyl)amino)carbonylmethyloxy-, (C5-C14)-arylamino-, an amino acid, N—((C1-C4)-alkylpiperidin-4-yloxy-, 2-methylsulfonylethoxy-, 1,3-thiazol-2-ylmethyloxy-, 3-pyridylmethyloxy-, 2-(di-((C1-C4)-alkyl)amino)-ethoxy and Q−(CH3)3N+—CH2—CH2—O— in which Q− is a physiologically tolerable anion; n is zero, one, two, three, four or five; m is zero, one, two, three, four or five: i is zero or one; q is zero, one or two; r is zero, one or two; s is zero, one, two or three; t is zero, one, two, three, four, five, six, seven or eight; p is zero, one or two, where all numbers p are independent of one another and can be identical or different; in all their stereoisomeric forms and mixtures thereof in all ratios, and their non-toxic, physiologically tolerable salts.
- 2. A compound of claim 1, wherein G is—(CR1R2)n—A—(CR—1R2)m—(CR1—R3)l—(CR1R2)q—R4 A is selected from the group consisting of a direct bond, —C(O)NR5—, —NR5C(O)—, —C(O)—, —NR5—, —O—, —S—, —S(O)2—, (C2-C4)-alkenediyl, (C2-C4)-alkenediyl, (C5-C14)-arylene where in the arylene residue one, two, three, four or five ring carbon atoms can be replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, and a divalent residue of a 3-membered to 7-membered saturated or unsaturated ring which can contain one or two ring heteroatoms selected from the group consisting of nitrogen, sulfur and oxygen and which can be monosubstituted or disubstituted by a member selected from the group consisting of ═O, ═S and R3; B is selected from the group consisting of (C1-C12)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl, (C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C8)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C1-C6)-alkoxy, (C1-C6)-alkoxy-(C1-C6)-alkyl, (C1-C6)-alkylcarbonyl-, (5-C14)-arylcarbonyl-, (5-C14)-aryl-(1-C8)-alkylcarbonyl-, (C1-C6)-alkylaminocarbonyl-, (C1-C6)-alkanoylamino-, (C1-C6)-alkylsulfonylamino-, (C5-C14)-aryl-sulfonylamino-, (C1-C14)-alkylamino-, di((C1-C6)-alkyl)amino-, (C1-C6)-alkylsulfonyl-, (C5-C14)-arylsulfonyl-, (C5-C14)-aryl-(C1-C8)-alkylsulfonyl-, (C5-C14)-aryl and (C5-C14)-heteroaryl, where all Bs are independent of one another and can be identical or different; X is selected from the group consisting of hydrogen, NH2, —NH—C(O)—R6 and OH; Y is hydrogen, Z is N; R1 and R2 are individually selected from the group consisting of hydrogen, fluorine, chlorine, cyano, nitro, (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C3-C14-)-cycloalkyl-(C1-C8)-alkyl-, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C8)-alkyl-, R6—O—R7, R6—S(O)p—R7, R6S(O)2NHR7, R6OC(O)NHR7 and R6R6+N—R7; R3 is selected from the group consisting of hydrogen, fluorine, chlorine, cyano, nitro, (C1-C18)-alkyl, (C2-C18)-alkenyl, (C2-C18)-alkynyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8-alkyl-, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl-,(C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C8)-alkyl-, R6—O—R7, R6R6+R7, R6C(O)—O—R7, R6C(O)R7, R6OC(O)R7), (R6N(R6)C(O)OR7, R6S(O)pN(R5)R7, R6OC(O)N(R5)R7, R6C(O)N(R5)R7, R6N(R6+)C(O)N(R5)R7, R6N(R6+)S(O)pN(R5)R7, R6S(O)pR7, R6SC(O)N(R5)R7, R6N(R6+)C(O)R7 and R6N(R6+)S(O)pR7, where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by a member selected from the group consisting of R6, fluorine, chlorine, bromine, cyano, trifluoromethyl, R6R6+NR7, nitro, R6OC(O)R7, R6C(O)R7, R6N(R6+)C(O)R7, R6N(R6+)S(O)pR7 and R6—O—R7, and where R3S are independent of one another and can be identical or different; and where all R3 are independent of one another and can be identical or different; R4 is selected from the group consisting of —C(O)R8, —C(S)R8, —S(O)pR8, —S(O)pR8; R5 is selected from the group consisting of hydrogen, (C1-C10)-alkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl- and (C5-C14)-aryl-(C1-C8)-alkyl-, where all R5 are independent of one another and can be identical or different; R6 and R6+ are individually selected from the group consisting of hydrogen, (C1-C18)-alkyl, (C3-C18)-alkyl, (C3-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl and (C5-C14)-heteroaryl-(C1-C8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by individual substituents selected from the group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C1-C6)-alkyl, (C1-C6)-alkoxyl, (C1-6)-alkoxy-(C1-C6)-alkyl-, (C1-C6)-alkoxycarbonyl-, (C1-C6)-alkylcarbonyl-, (C1-C6)-alkylaminocarbonyl-, (C1-C6)-alkoxy-(C1-C6)-alkoxy-, (C5-C14)-arylcarbonyl-, (C5-C14)-aryl-(C1-C8)-alkylcarbonyl-, (C1-C6)-alkanoylamino-, (C5-C14)-arylsulfonylamino-, (C1-C6)-alkylsulfonylamino-, (C1-C6)-alkylamino-, di((C1-C6)-alkyl)amino-, (C1-C6)-alkylsulfonyl, (C1-C6)-alkylaminosulfonyl-, (C5-C14)-arylaminosulfonyl-, (C5-C14)-aryl-(C1-C8)-alkylaminosulfonyl, (C5-C14)-arylsulfonyl-, (C5-C14)-aryl-(C1-C8)-alkylsulfonyl, (C5-C14)-aryl and (C5-C14)-heteroaryl; R7 is (C1-C4)-alkanediyl or a direct bond, where all R7 are independent of one another and can be identical or different; R8 and R8+ are individually selected from the group consisting of hydroxy, (C1-C8)-alkoxy, (C5-C14)-aryl-(C1-C4)-alkoxy-, (C5-C14)-aryloxy, (C1-C8)-alkylcarbonyloxy-(C1-C4)-alkoxy-, (C5-C14)-aryl-(C1-C8)-alkylcarbonyloxy-(C1-C8)-alkoxy-, NR6R6, (di-((C1-C8)-alkyl)amino)carbonylmethyloxy-, (di((C5-C14)-aryl-(C1-C8)-alkyl)amino)carbonylmethyloxy-, (C5-C14)-arylamino-, an amino acid, N—((C1-C4)-alkylpiperidin-4-yloxy-, 2-methylsulfonylethoxy-, 1,3-thiazol-2-ylmethyloxy-, 3-pyridylmethyloxy-, 2-(di-((C1-C4)-alkyl)amino)-ethoxy and Q−(CH3)3N+—CH2—CH2—O— in which Q− is a physiologically tolerable anion; n is zero, one, two, three, four or five; m is zero, one, two, three, four or five; i is zero or one; q is zero, one or two; r is zero, one or two; s is zero, one two or three; t is zero, one, two, three, four, five, six, seven or eight; p is zero, one or two, where all numbers p are independent of one another and can be identical or different; in all their stereoisomeric forms and mixtures thereof in all ratios, and their non-toxic, physiologically tolerable salts.
- 3. A compound of claim 1, wherein G is—(CR1R2)n—A—(CR—1R2)m—(CR1—R3)l—(CR1R2)q—R4 A is selected from the group consisting of a direct bond, —C(O)NR5—, —NR5C(O)—, —C(O)—, —NR— and (C5-C14)-arylene where in the arylene, one, two, three, four or five ring carbon atoms can be replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; B is selected from the group consisting of (C1-C6)-alkyl, chlorine, hydroxy, cyano, trifluoromethyl, (C1-C6)-alkoxy, (C1-C6)-alkylcarbonyl-(C1-C6)-alkanoylamino-, (C1-C6)-alkylamino and di((C1-C6)-alkyl)-amino-, where all Bs are independent of one another and can be identical or different; X is hydrogen; Y is hydrogen; Z is N; R1 and R2 are individually selected from the group consisting of hydrogen, (C1-C4)-alkyl, R6S(O)—NHR7 and R6OC(O)NHR7; R3 is selected from the group consisting of hydrogen, (C1-C12)-alkyl, (C2-C18)-alkenyl, (C2-C18)-alkynyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-C1-C6)-alkyl, (C5-C14)-aryl-(C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C6)-alkyl-, RR6—O—R7, R6—S(O)p—R7, R6S(O)2NHR7, R6OC(O)NHR7 and R6R6+N—R7; R4 is —C(O)R8; R5 is hydrogen or (C1-C4)-alkyl, where are R5s are independent of one another and can be identical or different; R6 and R6+ are individually hydrogen, (C1-C12)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C5-C14)-aryl-, (C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14-heteroaryl and (C5-C14)-heteroaryl-(C1-C8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by individual substituents selected from the group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkylamino-, di((C1-C6)-alkyl)amino-, (C5-C14)-aryl and (C5-C14)-heteroaryl, and where all R6s and R6+s are independent of one another and can be identical or different; R7 is (C1-C2)-alkanediyl or a direct bond, where all R7s are independent of one another and can be identical or different; R8 is hydroxy or (C1-C6)-alkoxy, n is zero, one, two, three, four or five; m is zero or one; i is zero or one; q is zero or one; r is zero or one; s is zero, one or two; t is zero, one, two, three or four; in all their stereoisomeric forms and mixtures thereof in all ratios, and their non-toxic physiologically tolerable salts.
- 4. A compound of claim 1, wherein G is—(CR1R2)n—A—(CR—1R2)m—(CR1—R3)l—(CR1R2)q—R4 A is a direct bond; B is (C1-C6)-alkyl or hydroxy, where all Bs are independent of one another and can be identical or different; X is hydrogen; Y is hydrogen; Z is n; R1 and R2 are individually selected from the group consisting of hydrogen, (C1-C4)-alkyl, R6S(O)—NHR7 and R6OC(O)NHR7; R3 is selected from the group consisting of hydrogen, (C1-C12)-alkyl, (C2-C18)-alkenyl, (C2-C18)-alkynyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C6)-alkyl, C5-C14)-aryl-(C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C6)-alkyl-, R6R6N—R7, R6S(O)pN(R5)R7, R6OC(O)N(R5)R7, and R6C(O)N(R5)R7, where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by a member selected from the group consisting of R6, fluorine, chlorine, trifluoromethyl, R6C(O)R7 and R6—O—R7; R4 is —C(O)R8; R5 is hydrogen or (C1-C4)-alkyl; R6 and R6+ are individually hydrogen, (C1-C12)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8-alkyl-, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl or (C5-C14)-heteroaryl-(C1-C8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by at least one substituent selected from the group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkylamino-, di((C1-C6)-alkyl)amino-, (C5-C14)-aryl and (C5-C14)-heteroaryl, and where all R6s and R6+s are independent of one another and can be identical or different; R7 is a direct bond; R8 is hydroxy or (C1-C4)-alkoxy; n is zero, one or two; m is zero or one; i is zero or one; q is zero or one; r is zero or one; s is zero, one or two; t is zero; in all their stereoisomeric forms and mixtures thereof in all ratios, and their nontoxic, physiologically tolerable salts.
- 5. A compound of claim 1 wherein G is—(CR1R2)n—A—(CR—1R2)m—(CR1—R3)l—(CR1R2)q—R4 A is a direct bond; X is hydrogen; Z is N; R1 and R2 are hydrogen or (C1-C2)-alkyl, where all R1s and R2s are independent of one another and can be identical or different; R3 is selected form the group consisting of R6R6+N—R7, R6S(O)2N(R5)R7 and R6C(O)N(R5)R7; R4 is —C(O)R8; R5 is hydrogen or (C1-C2)-alkyl; R6 and R6+ are individually selected from the group consisting of hydrogen, (C1-C12)-alkyl, (C1-C12)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-cycloalkyl-(C1-C8)-alkyl-, (C5-C14)-aryl-, (C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl, (C5-C14)-heteroaryl and (C5-C14)-heteroaryl-(C1-C8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by at least one substituent selected from the group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkylamino-, di((C1-C6)-alkyl)amino-, (C5-C14)-aryl and (C5-C14)-heteroaryl, and where all R6s and R6+s are independent of one another and can be identical or different; R7 is a direct bond; R8 is hydroxy or (C1-C4)-alkoxy; n is zero, one or two; m is zero or one; i is zero or one; q is zero or one; r is zero; s is zero; t is zero; in all their stereoisomeric forms and mixtures thereof in all ratios, and their non-eoxic, physiologically tolerable salts.
- 6.—(CR1R2)n—A—(CR—1R2)m—(CR1—R3)l—(CR1R2)q—R4 A is a direct bond; X is hydrogen; Z is N; R1 and R2 are hydrogen; R3 is R6S(O)2N(R5)R7 and R6C(O)N(R5)R7; R4 is —C(O)R8; R5 is hydrogen; R6 is selected from the group consisting of (C1-C12)-alkyl, (C1-C12)-alkyl, (C3-C14)-cycloalkyl, (C3-C14)-)-aryl, (C5-C14)-aryl-(C1-C8)-alkyl-, (C5-C14)-heteroaryl and (C5-C14)-heteroaryl-(C1-C8)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by at least one substituent selected from the group consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, (C1-C6)-alkylamino-, di((C1-C6)-alkyl)amino-, (C5-C14)-aryl and (C5-C14)-heteroaryl, R7 is a direct bond; R8 is hydroxy (C1-C4)-alkoxy; n is one; m is zero; i is one; q is zero; r is zero; s is zero; t is zero; in all their stereoisomeric forms and mixtures thereof in all ratios, and their non-toxic, physiologically tolerable salts.
- 7. A process for the preparation of a compound of claim 1 comprising reacting a compound of the formula VI with a compound of the formula VIIa or of formula VIIb wherein L1 is a cleaving group and B, G, X, Y, r, s and t are defined as in claim 1 but wherein functional groups can also be present in the form of precursor groups or in protected form.
- 8. A pharmaceutical composition, comprising an amount of a compound of claim 1 sufficient to treat osteoporosis and a pharmaceutically acceptable carrier.
- 9. A method of treating osteoporosis in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound of claim 1 sufficient to treat osteoporosis.
Priority Claims (1)
Number |
Date |
Country |
Kind |
99112636 |
Jul 1999 |
EP |
|
Parent Case Info
This application is a 371 of PCT/EP00/05920 filed Jun. 26, 2000.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/EP00/05920 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/02398 |
1/11/2001 |
WO |
A |
US Referenced Citations (3)
Foreign Referenced Citations (7)
Number |
Date |
Country |
0853084 |
Jul 1998 |
EP |
9532710 |
Dec 1995 |
WO |
9808940 |
Mar 1998 |
WO |
0818461 |
May 1998 |
WO |
9831359 |
Jul 1998 |
WO |
9932457 |
Jul 1999 |
WO |
9937621 |
Jul 1999 |
WO |